These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 26749044)
1. ERBB-2 overexpression as a risk factor for malignant phaeochromocytomas and paraganglinomas. Wang W; Zhong X; Ye L; Qi Y; Su T; Wei Q; Xie J; Jiang L; Jiang Y; Zhou W; Cui B; Ning G Clin Endocrinol (Oxf); 2016 Jun; 84(6):822-9. PubMed ID: 26749044 [TBL] [Abstract][Full Text] [Related]
2. Establishment and evaluation of a novel biomarker-based nomogram for malignant phaeochromocytomas and paragangliomas. Zhong X; Ye L; Su T; Xie J; Zhou W; Jiang Y; Jiang L; Ning G; Wang W Clin Endocrinol (Oxf); 2017 Aug; 87(2):127-135. PubMed ID: 28429830 [TBL] [Abstract][Full Text] [Related]
3. Value of Immunohistochemical Expression of Apelin, Succinate Dehydrogenase B, Chromogranin B, Human Epidermal Growth Factor Receptor-2, Contactin 4, and Succinyl-CoA Synthetase Subunit Beta in Differentiating Metastatic From Non-Metastatic Pheochromocytoma and Paraganglioma. Wang Y; Chen D; Pang Y; Xu X; Guan X; Liu L Front Endocrinol (Lausanne); 2022; 13():882906. PubMed ID: 35574028 [TBL] [Abstract][Full Text] [Related]
4. MicroRNA-210 May Be a Preoperative Biomarker of Malignant Pheochromocytomas and Paragangliomas. Ruff SM; Ayabe RI; Malekzadeh P; Good ML; Wach MM; Gonzales MK; Tirosh A; Nilubol N; Pacak K; Kebebew E; Patel D J Surg Res; 2019 Nov; 243():1-7. PubMed ID: 31146085 [TBL] [Abstract][Full Text] [Related]
5. Expression of Contactin 4 Is Associated With Malignant Behavior in Pheochromocytomas and Paragangliomas. Evenepoel L; van Nederveen FH; Oudijk L; Papathomas TG; Restuccia DF; Belt EJT; de Herder WW; Feelders RA; Franssen GJH; Hamoir M; Maiter D; Ghayee HK; Shay JW; Perren A; Timmers HJLM; van Eeden S; Vroonen L; Aydin S; Robledo M; Vikkula M; de Krijger RR; Dinjens WNM; Persu A; Korpershoek E J Clin Endocrinol Metab; 2018 Jan; 103(1):46-55. PubMed ID: 28938490 [TBL] [Abstract][Full Text] [Related]
6. Mass spectrometry imaging identifies metabolic patterns associated with malignant potential in pheochromocytoma and paraganglioma. Murakami M; Sun N; Greunke C; Feuchtinger A; Kircher S; Deutschbein T; Papathomas T; Bechmann N; William Wallace P; Peitzsch M; Korpershoek E; Friemel J; Gimenez-Roqueplo AP; Robledo M; J L M Timmers H; Canu L; Weber A; R de Krijger R; Fassnacht M; Knösel T; Kirchner T; Reincke M; Karl Walch A; Kroiss M; Beuschlein F Eur J Endocrinol; 2021 Jun; 185(1):179-191. PubMed ID: 33983135 [TBL] [Abstract][Full Text] [Related]
7. Disentangling of Malignancy from Benign Pheochromocytomas/Paragangliomas. Kim KY; Kim JH; Hong AR; Seong MW; Lee KE; Kim SJ; Kim SW; Shin CS; Kim SY PLoS One; 2016; 11(12):e0168413. PubMed ID: 27992508 [TBL] [Abstract][Full Text] [Related]
8. Germline mutations and genotype-phenotype correlations in patients with apparently sporadic pheochromocytoma/paraganglioma in Korea. Kim JH; Seong MW; Lee KE; Choi HJ; Ku EJ; Bae JH; Park SS; Choi SH; Kim SW; Shin C; Kim SY Clin Genet; 2014 Nov; 86(5):482-6. PubMed ID: 24134185 [TBL] [Abstract][Full Text] [Related]
9. Epidemiology and Prognosis of Pheochromocytoma/Paraganglioma in Korea: A Nationwide Study Based on the National Health Insurance Service. Kim JH; Moon H; Noh J; Lee J; Kim SG Endocrinol Metab (Seoul); 2020 Mar; 35(1):157-164. PubMed ID: 32207276 [TBL] [Abstract][Full Text] [Related]
10. Semiquantitative 123I-Metaiodobenzylguanidine Scintigraphy to Distinguish Pheochromocytoma and Paraganglioma from Physiologic Adrenal Uptake and Its Correlation with Genotype-Dependent Expression of Catecholamine Transporters. van Berkel A; Rao JU; Lenders JW; Pellegata NS; Kusters B; Piscaer I; Hermus AR; Plantinga TS; Langenhuijsen JF; Vriens D; Janssen MJ; Gotthardt M; Timmers HJ J Nucl Med; 2015 Jun; 56(6):839-46. PubMed ID: 25883126 [TBL] [Abstract][Full Text] [Related]
11. Overexpression of ERBB-2 was more frequently detected in malignant than benign pheochromocytomas by multiplex ligation-dependent probe amplification and immunohistochemistry. Yuan W; Wang W; Cui B; Su T; Ge Y; Jiang L; Zhou W; Ning G Endocr Relat Cancer; 2008 Mar; 15(1):343-50. PubMed ID: 18310300 [TBL] [Abstract][Full Text] [Related]
12. Prognostic value of p53, bcl-2, and c-erbB-2 protein expression in phaeochromocytomas. de Krijger RR; van der Harst E; van der Ham F; Stijnen T; Dinjens WN; Koper JW; Bruining HA; Lamberts SW; Bosman FT J Pathol; 1999 May; 188(1):51-5. PubMed ID: 10398140 [TBL] [Abstract][Full Text] [Related]
13. Genetic Characteristics of Incidental Pheochromocytoma and Paraganglioma. Zhang J; Li M; Pang Y; Wang C; Wu J; Cheng Z; Li X; Lu Z; Liu Y; Guo J; Chen X; He Y; Guan X; Xu X; Wang Y; Liu J; Guo W; Hou Y; Liu L; Jiang J; Gao X J Clin Endocrinol Metab; 2022 Apr; 107(5):e1835-e1842. PubMed ID: 35106577 [TBL] [Abstract][Full Text] [Related]
14. New Insights into the Nuclear Imaging Phenotypes of Cluster 1 Pheochromocytoma and Paraganglioma. Taïeb D; Pacak K Trends Endocrinol Metab; 2017 Nov; 28(11):807-817. PubMed ID: 28867159 [TBL] [Abstract][Full Text] [Related]
15. Proliferative index in phaeochromocytomas: does it predict the occurrence of metastases? van der Harst E; Bruining HA; Jaap Bonjer H; van der Ham F; Dinjens WN; Lamberts SW; de Herder WW; Koper JW; Stijnen T; Proye C; Lecomte-Houcke M; Bosman FT; de Krijger RR J Pathol; 2000 Jun; 191(2):175-80. PubMed ID: 10861578 [TBL] [Abstract][Full Text] [Related]
16. Clinical differences between small and large pheochromocytomas and paragangliomas. Zhao L; Li Z; Meng X; Fan H; Zhang Z; Zhang Z; Liu Y; Zhou X; Zhu H Front Endocrinol (Lausanne); 2023; 14():1087506. PubMed ID: 36967797 [TBL] [Abstract][Full Text] [Related]
17. Characteristics of Intraoperative Hemodynamic Instability in Postoperatively Diagnosed Pheochromocytoma and Sympathetic Paraganglioma Patients. Kim JH; Lee HC; Kim SJ; Lee KE; Jung KC Front Endocrinol (Lausanne); 2022; 13():816833. PubMed ID: 35282440 [TBL] [Abstract][Full Text] [Related]
18. New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification. Crona J; Taïeb D; Pacak K Endocr Rev; 2017 Dec; 38(6):489-515. PubMed ID: 28938417 [TBL] [Abstract][Full Text] [Related]
19. Recommendations for somatic and germline genetic testing of single pheochromocytoma and paraganglioma based on findings from a series of 329 patients. Currás-Freixes M; Inglada-Pérez L; Mancikova V; Montero-Conde C; Letón R; Comino-Méndez I; Apellániz-Ruiz M; Sánchez-Barroso L; Aguirre Sánchez-Covisa M; Alcázar V; Aller J; Álvarez-Escolá C; Andía-Melero VM; Azriel-Mira S; Calatayud-Gutiérrez M; Díaz JÁ; Díez-Hernández A; Lamas-Oliveira C; Marazuela M; Matias-Guiu X; Meoro-Avilés A; Patiño-García A; Pedrinaci S; Riesco-Eizaguirre G; Sábado-Álvarez C; Sáez-Villaverde R; Sainz de Los Terreros A; Sanz Guadarrama Ó; Sastre-Marcos J; Scolá-Yurrita B; Segura-Huerta Á; Serrano-Corredor Mde L; Villar-Vicente MR; Rodríguez-Antona C; Korpershoek E; Cascón A; Robledo M J Med Genet; 2015 Oct; 52(10):647-56. PubMed ID: 26269449 [TBL] [Abstract][Full Text] [Related]
20. Malignant Pheochromocytoma and Paraganglioma: 272 Patients Over 55 Years. Hamidi O; Young WF; Iñiguez-Ariza NM; Kittah NE; Gruber L; Bancos C; Tamhane S; Bancos I J Clin Endocrinol Metab; 2017 Sep; 102(9):3296-3305. PubMed ID: 28605453 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]